In contrast, therapies targeting OX40-OX40L signaling may provide additional therapeutic benefits to patients with varying AD phenotypes and endotypes, including those who do not adequately respond to treatments that target specific components of the TH2 pathway. Here, TNFRSF4 is linked to Alzheimer disease.